Complete financial analysis of Lexicon Pharmaceuticals, Inc. (LXRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexicon Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MAV Beauty Brands Inc. (MAVBF) Income Statement Analysis – Financial Results
- Axsome Therapeutics, Inc. (AXSM) Income Statement Analysis – Financial Results
- Century Lithium Corp. (CYDVF) Income Statement Analysis – Financial Results
- Vicarious Surgical Inc. (RBOT) Income Statement Analysis – Financial Results
- Sincere Security Corp. Ltd. (6721.TWO) Income Statement Analysis – Financial Results
Lexicon Pharmaceuticals, Inc. (LXRX)
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.20M | 139.00K | 298.00K | 24.00M | 322.07M | 63.21M | 90.34M | 83.34M | 130.01M | 22.85M | 2.22M | 1.09M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 14.46M | 4.70M |
| Cost of Revenue | 85.00K | 427.00K | 55.05M | 1.93M | 3.23M | 2.49M | 1.90M | 163.97M | 95.19M | 89.28M | 89.68M | 82.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.62M | -2.00M |
| Gross Profit | 1.12M | -288.00K | -54.75M | 22.07M | 318.84M | 60.72M | 88.44M | -80.64M | 34.83M | -66.43M | -87.46M | -81.49M | 1.85M | 4.91M | 10.70M | 32.32M | 50.12M | 72.80M | 75.68M | 61.74M | 42.84M | 35.20M | 305.58M | 17.08M | 6.70M |
| Gross Profit Ratio | 92.94% | -207.19% | -18,371.81% | 91.96% | 99.00% | 96.06% | 97.90% | -96.76% | 26.79% | -290.65% | -3,936.09% | -7,482.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 118.13% | 142.55% |
| Research & Development | 58.89M | 52.82M | 55.05M | 153.62M | 91.92M | 100.24M | 156.81M | 178.15M | 95.19M | 89.28M | 89.68M | 82.57M | 91.83M | 75.35M | 81.24M | 108.58M | 104.33M | 106.70M | 93.63M | 90.59M | 82.20M | 74.86M | 53.36M | 31.65M | 14.60M |
| General & Administrative | 0.00 | 48.08M | 0.00 | 0.00 | 0.00 | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 0.00 | 0.00 | 0.00 | 0.00 | 20.86M | 18.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 113.98M | 48.08M | 32.34M | 47.23M | 56.84M | 63.75M | 66.20M | 43.04M | 23.84M | 19.41M | 17.12M | 17.04M | 17.35M | 22.57M | 19.42M | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 20.86M | 18.29M | 2.90M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 1.60M | 28.64M | 0.00 | 1.95M | 2.29M | 572.00K | 2.26M | 59.00K | 105.00K | 24.12M | 2.71M | 0.00 | 20.28M | 20.74M | 21.33M | 18.17M | 18.61M | 23.23M | 23.23M | 275.00M | 2.62M | 4.90M |
| Operating Expenses | 172.87M | 100.90M | 87.39M | 200.85M | 148.76M | 164.00M | 223.02M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 52.56M | 19.50M |
| Cost & Expenses | 172.95M | 100.90M | 87.39M | 202.78M | 151.99M | 166.49M | 224.92M | 221.20M | 119.02M | 108.69M | 106.80M | 99.62M | 115.94M | 100.63M | 100.66M | 128.86M | 125.07M | 128.03M | 111.80M | 109.19M | 105.43M | 98.09M | 349.22M | 49.94M | 17.50M |
| Interest Income | 7.73M | 1.60M | 134.00K | 2.77M | 3.35M | 3.51M | 1.95M | 2.29M | 572.00K | 2.26M | 157.00K | 213.00K | 255.00K | 519.00K | 880.00K | 5.76M | 7.29M | 3.65M | 2.65M | 1.64M | 1.80M | 3.23M | 8.78M | 9.90M | 0.00 |
| Interest Expense | 13.10M | 2.78M | 802.00K | 14.54M | 20.68M | 20.78M | 6.98M | 6.57M | 6.72M | 2.25M | 1.97M | 2.11M | 2.53M | 2.72M | 2.97M | 2.69M | 2.77M | 3.25M | 3.28M | 2.66M | 325.00K | 7.00K | 314.00K | 422.04K | 0.00 |
| Depreciation & Amortization | 554.00K | 427.00K | 292.00K | 2.93M | 3.65M | 3.68M | 3.40M | 2.06M | 727.00K | 1.93M | 2.86M | 4.19M | 4.89M | 5.39M | 6.16M | 10.07M | 10.42M | 11.20M | 11.64M | 12.87M | 21.53M | 20.58M | 16.55M | 2.62M | 2.00M |
| EBITDA | -163.46M | -98.74M | -86.66M | -41.10M | 173.74M | -96.09M | -125.27M | -125.82M | 11.72M | -96.18M | -99.29M | -103.91M | -108.80M | -93.69M | -84.29M | -86.26M | -64.53M | -39.98M | -24.48M | -34.58M | -41.06M | -42.31M | -27.09M | -32.86M | -10.80M |
| EBITDA Ratio | -13,576.74% | -71,341.01% | -29,179.87% | -733.56% | 53.85% | -157.84% | -146.82% | -162.67% | 8.89% | -365.72% | -4,696.89% | -9,018.37% | -6,156.84% | -1,939.67% | -832.49% | -256.94% | -127.18% | -61.03% | -33.09% | -58.12% | -95.86% | -120.21% | -8.86% | -227.24% | -229.79% |
| Operating Income | -171.75M | -100.76M | -87.09M | -178.79M | 141.45M | -103.28M | -136.68M | -137.16M | 1.47M | -100.37M | -102.37M | -108.42M | -114.10M | -95.72M | -89.96M | -96.54M | -74.95M | -55.23M | -36.12M | -47.45M | -62.59M | -62.89M | -43.64M | -35.48M | -12.80M |
| Operating Income Ratio | -14,264.95% | -72,489.21% | -29,224.83% | -745.09% | 43.92% | -163.39% | -151.30% | -164.58% | 1.13% | -439.16% | -4,607.16% | -9,955.46% | -6,170.63% | -1,950.24% | -840.71% | -298.68% | -149.56% | -75.87% | -47.73% | -76.86% | -146.12% | -178.67% | -14.28% | -245.37% | -272.34% |
| Total Other Income/Expenses | -5.37M | -1.18M | -668.00K | -10.77M | -17.33M | -17.27M | -5.03M | -4.27M | -6.15M | 2.00K | -1.76M | -1.80M | -2.12M | -6.08M | -3.46M | -349.00K | 3.72M | 801.00K | -77.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -177.12M | -101.94M | -87.76M | -58.57M | 124.12M | -120.55M | -141.71M | -141.43M | -4.68M | -100.36M | -104.13M | -110.21M | -116.22M | -101.80M | -93.42M | -96.88M | -71.23M | 54.43M | 39.20M | -46.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -14,710.88% | -73,341.01% | -29,448.99% | -244.11% | 38.54% | -190.71% | -156.87% | -169.71% | -3.60% | -439.15% | -4,686.14% | -10,120.39% | -6,285.29% | -2,074.19% | -873.07% | -299.76% | -142.13% | 74.77% | 51.79% | -74.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.18M | 510.00K | 11.61M | -6.01M | 3.51M | -12.66M | 4.51M | 6.00M | -70.00K | -833.00K | -1.97M | -2.36M | -26.00K | -102.00K | -19.68M | -16.16M | -119.00K | 119.00K | -282.00K | 1.61M | -3.22M | -8.47M | -9.48M | -300.00K |
| Net Income | -177.12M | -103.13M | -88.27M | -70.18M | 130.13M | -120.55M | -129.05M | -141.43M | -4.68M | -100.29M | -104.13M | -110.21M | -116.22M | -101.78M | -82.78M | -76.86M | -58.79M | -54.31M | -36.32M | -47.17M | -64.20M | -59.67M | -35.17M | -25.99M | -12.50M |
| Net Income Ratio | -14,710.88% | -74,192.81% | -29,620.13% | -292.49% | 40.40% | -190.71% | -142.86% | -169.71% | -3.60% | -438.85% | -4,686.14% | -10,120.39% | -6,285.29% | -2,073.66% | -773.64% | -237.80% | -117.31% | -74.61% | -47.98% | -76.40% | -149.86% | -169.52% | -11.51% | -179.78% | -265.96% |
| EPS | -0.80 | -0.62 | -0.61 | -0.63 | 1.23 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| EPS Diluted | -0.80 | -0.62 | -0.61 | -0.63 | 1.11 | -1.14 | -1.23 | -1.36 | -0.05 | -1.31 | -1.42 | -1.58 | -2.39 | -2.35 | -3.98 | -3.93 | -4.12 | -5.68 | -3.97 | -5.21 | -7.91 | -7.99 | -4.90 | -4.37 | -3.57 |
| Weighted Avg Shares Out | 221.13M | 165.73M | 145.65M | 110.84M | 106.22M | 105.74M | 105.12M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
| Weighted Avg Shares Out (Dil) | 221.13M | 165.73M | 145.65M | 110.84M | 116.75M | 105.83M | 105.24M | 103.86M | 103.59M | 76.35M | 73.30M | 69.96M | 48.68M | 43.26M | 20.78M | 19.54M | 14.26M | 9.55M | 9.14M | 9.05M | 8.12M | 7.47M | 7.17M | 5.95M | 3.50M |
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug...
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH , Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced...
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon's novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024....
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September:
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
Source: https://incomestatements.info
Category: Stock Reports